Actavis (ACT) PT Lifted to $352 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Actavis (ACT) PT Lifted to $340 at Argus
February 20, 2015 9:32 AM ESTArgus reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $340.00 (from $310.00), noting the company is gnerating strong growth, while also preparing for the Allergan acquisition.
The firm is boosting 2015 stand-alone adj-EPS from $16.55 to $16.80, indicating 20% growth. The stock... More
Actavis (ACT) Receives FDA Approval for Generic Subutex ANDA
February 20, 2015 8:46 AM ESTActavis (NYSE: ACT) announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex® (Buprenorphine 2 mg and 8 mg sublingual tablets). Actavis intends to begin shipping... More
Actavis (ACT) PT Lifted to $345 at Guggenheim Following Q4 Results and Update
February 18, 2015 4:23 PM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from $300.00) following Q4 results and outlook.
Chen comments, "We are raising our PT to $345 from $300 post a 4Q14 beat and strong outlook for '15. We use a... More
